You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Policy & Regulation
Calidi Biotherapeutics Names Heehyoung Lee to Board of Directors
Login
Username:

Password:


Related Headlines

Tyra Biosciences to announce TYRA-300 preclinical results at ENDO 2025

Centivax raises USD45m to commercialise universal flu vaccine

Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation

Avenzo Therapeutics doses first patient in AVZO-1418/DB-1418 Phase 1/2 clinical study

SCG Cell's SCG101V therapy Investigational New Drug Application receives Chinese regulatory approval 

KalVista secures FDA approval for EKTERLY, first oral on-demand HAE treatment

BioDlink convenes peer advisory event on innovation and collaboration strategies

CyanVac's nasal COVID vaccine shows promise in phase 1 trial

Imfinzi approved in EU as first perioperative immunotherapy for muscle-invasive bladder cancer

Akeso's bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials

Brii Biosciences enters BRII-693 licensing agreement with Joincare Group in Greater China

Neurizon enters global license agreement with Elanco to commercialise NUZ-001

Ascletis doses first US participants in ASC30 Phase IIa study for obesity treatment

Jacobio's JAB-8263 Phase I/II Clinical Trial IND application receives Chinese regulatory approval

RedHill Biopharma recruiting for expanded Phase 2 opaganib/darolutamide combination study in advanced prostate cancer

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2025